Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
C23H14O11Na2
CAS Number:
Molecular Weight:
512.33
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
239-926-7
MDL number:
Product Name
Cromolyn sodium salt, ≥95%
Quality Level
assay
≥95%
form
powder
originator
Sanofi Aventis
SMILES string
[Na].OC(COc1cccc2OC(=CC(=O)c12)C(O)=O)COc3cccc4OC(=CC(=O)c34)C(O)=O
InChI
1S/C23H16O11.Na.H/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30;;/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30);;
InChI key
UXMUBZWVLQEMRB-UHFFFAOYSA-N
General description
Cromolyn sodium is a mast stabilizer, which is used to treat allergies. It is a bischromone and functions as a non-steroidal anti-inflammatory drug. It inhibits the release of histamines from mast cells.
Application
Cromolyn sodium salt has been used to block mast cell activation and to inhibit histamine secretion from rodent peritoneal mast cells. It has also been used to stabilize mast cells.
Biochem/physiol Actions
Cromolyn blocks the release of histamine and other pro-inflammatory mediators from mast cells.
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Neuropeptide Initiated Mast Cell Activation by Transcutaneous Electrical Acupoint Stimulation of Acupoint LI4 in Rats
Chen LZ, et al.
Scientific Reports, 8(1), 13921-13921 (2018)
Mast cells and histamine are triggering the NF-kappaB-mediated reactions of adult and aged perilymphatic mesenteric tissues to acute inflammation
Nizamutdinova IT, et al.
Aging (Albany. NY.), 8(11), 3065-3065 (2016)
Reginald Gorczynski et al.
Transplantation, 97(1), 39-46 (2013-10-22)
Rejection is associated with early degranulation (≥80%) of graft-infiltrating CD200R1 receptor-positive mast cells (MCs). Survival is increased, and MC degranulation is decreased, in CD200 mice but not in CD200R1KO mice. CD200 engagement of CD200R2 (not present on MCs) alters dendritic
